Meiji Yasuda Asset Management Co Ltd. Sells 99 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Meiji Yasuda Asset Management Co Ltd. reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,145 shares of the company’s stock after selling 99 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in IDEXX Laboratories were worth $473,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of IDXX. Flossbach Von Storch SE boosted its position in IDEXX Laboratories by 5,439.3% in the 4th quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock valued at $195,696,000 after buying an additional 464,791 shares during the last quarter. William Blair Investment Management LLC lifted its stake in shares of IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock valued at $174,527,000 after acquiring an additional 369,471 shares during the period. Assenagon Asset Management S.A. boosted its holdings in IDEXX Laboratories by 265.6% in the fourth quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company’s stock valued at $179,867,000 after acquiring an additional 316,048 shares during the last quarter. Seilern Investment Management Ltd acquired a new stake in IDEXX Laboratories in the fourth quarter worth about $113,104,000. Finally, Vontobel Holding Ltd. raised its holdings in IDEXX Laboratories by 90.1% during the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company’s stock worth $173,051,000 after purchasing an additional 198,404 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 1.2 %

NASDAQ IDXX opened at $422.54 on Friday. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The firm has a market cap of $34.25 billion, a P/E ratio of 39.60, a P/E/G ratio of 3.41 and a beta of 1.39. The stock’s 50-day moving average is $437.13 and its 200-day moving average is $443.72.

Analysts Set New Price Targets

IDXX has been the topic of several recent research reports. Morgan Stanley reduced their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Barclays raised their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $533.75.

Insider Buying and Selling

In related news, Director M Anne Szostak sold 3,000 shares of the company’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.